









Markets
/
Stocks
/
nasdaq-kura
/

Kura Oncology Inc

KURA

9.770USD

-0.500-4.87%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

848.01MMarket Cap

LossP/E TTM



Kura Oncology Inc

9.770

-0.500-4.87%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Kura Oncology Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kura Oncology Inc's Score

Industry at a Glance

Industry Ranking

36 / 407

Overall Ranking

126 / 4617

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Buy

Current Rating

27.000

Target Price

+162.90%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Kura Oncology Inc Highlights

StrengthsRisks

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Growing

The company is in a growing phase, with the latest annual income totaling USD 53.88M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 53.88M.

Fairly Valued

The company’s latest PE is -4.33, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 83.65M shares, decreasing 20.84% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 6.01K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.53.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 7.32, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

7.32

Change



Financials

6.38

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.01

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.99

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.23

Key Metrics

Free cash flow

No Data

Kura Oncology Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 7.50, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -4.33, which is -43.30% below the recent high of -2.46 and -160.48% above the recent low of -11.29.

Score

Industry at a Glance

Previous score

7.50

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 36/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 8.27, which is higher than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Kura Oncology Inc is 27.00, with a high of 40.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.27

Change

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Buy

Current Rating

27.000

Target Price

+162.90%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Kura Oncology Inc

KURA

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 7.09, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 10.90 and the support level at 8.79, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.25

Change

-0.16

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.100

Neutral

RSI(14)

51.105

Neutral

STOCH(KDJ)(9,3,3)

51.317

Sell

ATR(14)

0.719

Low Volatility

CCI(14)

-53.068

Neutral

Williams %R

60.757

Sell

TRIX(12,20)

0.549

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

10.250

Sell

MA10

9.995

Sell

MA20

9.968

Sell

MA50

9.030

Buy

MA100

7.658

Buy

MA200

7.313

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 96.38%, representing a quarter-over-quarter increase of 0.37%. The largest institutional shareholder is The Vanguard, holding a total of 5.31M shares, representing 6.11% of shares outstanding, with 1.13% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Suvretta Capital Management, LLC

8.12M

+9.10%

BVF Partners L.P.

7.75M

BlackRock Institutional Trust Company, N.A.

7.05M

+8.33%

Armistice Capital LLC

6.20M

-5.66%

The Vanguard Group, Inc.

Star Investors

5.31M

+7.47%

EcoR1 Capital, LLC

4.20M

+59.07%

Prosight Capital

3.18M

+53.07%

State Street Investment Management (US)

3.04M

-7.47%

Millennium Management LLC

2.62M

+44.87%

Geode Capital Management, L.L.C.

2.01M

+11.73%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 5.25, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.